Search Results - "Flynt, Frederick L."

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
  2. 2

    Current approaches and challenges in monitoring treatment responses in breast cancer by Graham, Lindsey J, Shupe, Matthew P, Schneble, Erika J, Flynt, Frederick L, Clemenshaw, Michael N, Kirkpatrick, Aaron D, Gallagher, Chris, Nissan, Aviram, Henry, Leonard, Stojadinovic, Alexander, Peoples, George E, Shumway, Nathan M

    Published in Journal of Cancer (05-01-2014)
    “…Monitoring response to treatment is a key element in the management of breast cancer that involves several different viewpoints from surgery, radiology, and…”
    Get full text
    Journal Article
  3. 3

    Dedifferentiated Liposarcoma of the Retroperitoneum with Extensive Leiomyosarcomatous Differentiation and β-Human Chorionic Gonadotropin Production by Russell, Michael J., Flynt, Frederick L., Harroff, Allyson L., Fadare, Oluwole

    Published in Sarcoma (2008)
    “…Dedifferentiated liposarcomas may display a variety of “heterologous” lines of differentiation, including osseous, vascular, skeletal, and/or smooth muscular…”
    Get full text
    Journal Article
  4. 4

    Current approaches and challenges in early detection of breast cancer recurrence by Schneble, Erika J, Graham, Lindsey J, Shupe, Matthew P, Flynt, Frederick L, Banks, Kevin P, Kirkpatrick, Aaron D, Nissan, Aviram, Henry, Leonard, Stojadinovic, Alexander, Shumway, Nathan M, Avital, Itzhak, Peoples, George E, Setlik, Robert F

    Published in Journal of Cancer (01-01-2014)
    “…Early detection of breast cancer recurrence is a key element of follow-up care and surveillance after completion of primary treatment. The goal is to improve…”
    Get full text
    Journal Article
  5. 5

    Future directions for the early detection of recurrent breast cancer by Schneble, Erika J, Graham, Lindsey J, Shupe, Matthew P, Flynt, Frederick L, Banks, Kevin P, Kirkpatrick, Aaron D, Nissan, Aviram, Henry, Leonard, Stojadinovic, Alexander, Shumway, Nathan M, Avital, Itzhak, Peoples, George E, Setlik, Robert F

    Published in Journal of Cancer (01-01-2014)
    “…The main goal of follow-up care after breast cancer treatment is the early detection of disease recurrence. In this review, we emphasize the multidisciplinary…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Cytogenetic abnormalities precede morphological abnormalities in developing malignant conditions: Report of 2 cases by Symons, Wendy A., Flynt, Frederick L., Mendiola, Christina, Ortega, Veronica, Higgins, Russell A., Velagaleti, Gopalrao V.N.

    Published in Experimental and molecular pathology (01-02-2013)
    “…We previously hypothesized that cytogenetic abnormalities precede morphological abnormalities in developing malignant conditions. In this context we evaluated…”
    Get full text
    Journal Article
  8. 8

    MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-γ by Zhao, Mojun, Flynt, Frederick L., Hong, Mei, Chen, Han, Gilbert, Carolyn A., Briley, Nicole T., Bolick, Sophia C., Wright, Kenneth L., Piskurich, Janet F.

    Published in Molecular immunology (01-04-2007)
    “…The MHC class II transactivator (CIITA) acts in the cell nucleus as the master regulator of MHC class II (MHC II) gene expression. It is important to study…”
    Get full text
    Journal Article
  9. 9

    Future directions for monitoring treatment responses in breast cancer by Shupe, Matthew P, Graham, Lindsey J, Schneble, Erika J, Flynt, Frederick L, Clemenshaw, Michael N, Kirkpatrick, Aaron D, Stojadinovic, Alexander, Peoples, George E, Shumway, Nathan M

    Published in Journal of Cancer (05-01-2014)
    “…In the prior review, we outlined the current standard of care for monitoring treatment responses in breast cancer and discussed the many challenges associated…”
    Get full text
    Journal Article
  10. 10

    Dedifferentiated Liposarcoma of the Retroperitoneum with Extensive Leiomyosarcomatous Differentiation and -Human Chorionic Gonadotropin Production by Russell, Michael J., Flynt, Frederick L., Harroff, Allyson L., Fadare, Oluwole

    Published in Sarcoma (2008)
    “…Dedifferentiated liposarcomas may display a variety of “heterologous” lines of differentiation, including osseous, vascular, skeletal, and/or smooth muscular…”
    Get full text
    Journal Article
  11. 11

    Saline alone vs saline plus mannitol hydration for the prevention of acute cisplatin nephrotoxicity: A randomized trial by Beeler, Bradley, Delacruz, Wilfred P., Flynt, Frederick L., Terrazzino, Sandra, Hullinger, Naomi, Aden, James, Byrd, Tiffany, King, Melissa M., Nelson, Douglas A.

    Published in Journal of clinical oncology (20-10-2018)
    “…Abstract only 242 Background: Cisplatin is a widely used chemotherapeutic in treating malignancies. A common side effects of cisplatin is kidney injury, or…”
    Get full text
    Journal Article
  12. 12
  13. 13

    IFN-γ up-regulates expression of the MHC class II transactivator (CIITA) type IV promoter in multiple myeloma cells (35.20) by Piskurich, Janet F., Zhao, Mojun, Flynt, Frederick L., Hong, Mei, Chen, Han, Gilbert, Carolyn A, Briley, Nicole T

    Published in The Journal of immunology (1950) (01-04-2007)
    “…Abstract MHC Class II transactivator (CIITA) is the master transcriptional regulator of MHC class II (MHC II) genes. MHC II expression is central to antigen…”
    Get full text
    Journal Article
  14. 14

    MHC Class II Transactivator (CIITA) Expression is up Regulated in Multiple Myeloma Cells by IFN-γ by Zhao, Mojun, Flynt, Frederick L., Hong, Mei, Chen, Han, Gilbert, Carolyn A., Briley, Nicole T., Bolick, Sophia C., Wright, Kenneth L., Piskurich, Janet F.

    Published in Molecular immunology (14-02-2007)
    “…The MHC Class II transactivator (CIITA) acts in the cell nucleus as the master regulator of MHC class II (MHC II) gene expression. It is important to study…”
    Get full text
    Journal Article
  15. 15
  16. 16